The company’s report, "Bone Grafts and Substitutes, Global Outlook, 2015-2028," reveals that Asia Pacific will be one of the fastest growing regions at a CAGR of 5.4 percent between 2018 and 2028, with North America and Europe following closely behind at 2.7 percent and 2.9 percent, respectively.
Synthetic bone graft substitutes comprise the largest segment of the market, followed by allograft bone chips and bone morphogenetic proteins (BMP). Synthetic materials have been more easily acquired in the past, but organic products have been experiencing growth as they are approved in more countries.
Sarah Janer, medical devices analyst at GlobalData, said, “The increasing prevalence of osteoarthritis is driving the demand for procedures that include bone grafts and substitutes, such as spinal fusion, trauma fixation, and joint reconstruction surgeries.”
Barriers to market growth include a lack of clinical data on novel bone substitutes, and ongoing debates regarding many products cancer-related complications.
Janer concluded, “Although autograft bone grafts are considered the gold standard, lack of availability is driving demand for alternatives such as synthetic bone grafts and demineralized bone matrix products.”
Four thousand of the world’s largest companies, including over 70 percent of FTSE 100 and 60 percent of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData helps clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.